OpenAI acquires biotech startup Orchestra Bio to expand Rosalind AI
OpenAI announced on Tuesday the acquisition of Orchestra Bio to integrate its technology into the Rosalind AI model and Rosalind Workbench tool.
1 min read
What happened
OpenAI announced on Tuesday that it has acquired Orchestra Bio, a four-year-old AI biotech software startup [1]. While the financial terms of the deal were not disclosed, Orchestra Bio had reportedly raised approximately $20 million as of 2025 from investors including 8VC, Atria, and Andreessen Horowitz [1].
OpenAI plans to add the Orchestra Bio team and its technology to support two specific projects:
- Rosalind: An AI model designed for life sciences research [1].
- Rosalind Workbench: A tool intended to help researchers analyze results and plan experiments [1].
Orchestra Bio specializes in creating AI agents that assist biotech companies with drug discovery operations. These tools manage tasks such as resolving clinical trial scheduling issues and tracking finances [1]. OpenAI stated the acquisition aims to bring AI-powered operations to life sciences research and development to help biopharma teams accelerate drug development [2].
Who is affected
According to OpenAI, the company already has customers for the Rosalind model, including Moderna and Novo Nordisk [1]. The integration of Orchestra Bio’s technology is intended to assist biopharma teams in advancing new treatments [2].
Sources
- 1. OpenAI acquires startup Orchestra Bio to beef up its biotech business — TechCrunch
- 2. OpenAI acquires Orchestra Bio — OpenAI
Drafted with AI assistance from the reports above and checked automatically for sourcing. Always confirm dates, fees and requirements on the official website before acting. Report an error · How we correct mistakes
Comments
No comments yet. Share a question or what you know.